CoChat
Sign Up
Cited by 570Chemotherapy-induced cardiotoxicity and mitigationChildhood Cancer Survivors' Quality of LifeCardiac tumors and thrombi

Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group

Open access
Armenian, Saro H, Hudson, Melissa M, Mulder, Renee L, Chen, Ming Hui, Constine, Louis S, Dwyer, Mary, Nathan, Paul C, Tissing, Wim J E +9 more·2015·The Lancet Oncology
DOI 10.1016/s1470-2045(14)70409-7PMC PMC4485458
Open this paper in CoChat — free account

Abstract

Survivors of childhood cancer treated with anthracycline chemotherapy or chest radiation are at an increased risk of developing congestive heart failure. In this population, congestive heart failure is well recognised as a progressive disorder, with a variable period of asymptomatic cardiomyopathy that precedes signs and symptoms. As a result, several clinical practice guidelines have been developed independently to help with detection and treatment of asymptomatic cardiomyopathy. These guidelines differ with regards to definitions of at-risk populations, surveillance modality and frequency, and recommendations for interventions. Differences between these guidelines could hinder the effective implementation of these recommendations. We report on the results of an international collaboration to harmonise existing cardiomyopathy surveillance recommendations using an evidence-based approach that relied on standardised definitions for outcomes of interest and transparent presentation of the quality of the evidence. The resultant recommendations were graded according to the quality of the evidence and the potential benefit gained from early detection and intervention.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(14)70409-7

Cites

148 of 148 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Treatment for anthracycline-induced heart failure is similar to that of heart failure from any cause.

    “Treatment for anthracycline-induced heart failure is similar to that of heart failure from any cause 164 .”

    From Osteosarcoma (2022) · cites this paper as [164]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 43

  1. [1]van der Pal HJ van Dalen EC van Delden E High risk of symptomatic cardiac events in childhood cancer survivors J Clin Oncol 2012 30 1429 1437 22473161
  2. [2]Mulrooney DA Yeazel MW Kawashima T Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort BMJ 2009 339 b4606 19996459 PMC3266843
  3. [3]Blanco JG Sun CL Landier W Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group J Clin Oncol 2012 30 1415 1421 22124095 PMC3383117
  4. [4]Temming P Qureshi A Hardt J Prevalence and predictors of anthracycline cardiotoxicity in children treated for acute myeloid leukaemia: retrospective cohort study in a single centre in the United Kingdom Pediatr Blood Cancer 2011 56 625 630 21298750
  5. [9]Uderzo C Pillon M Corti P Impact of cumulative anthracycline dose, preparative regimen and chronic graft-versus-host disease on pulmonary and cardiac function in children 5 years after allogeneic hematopoietic stem cell transplantation: a prospective evaluation on behalf of the EBMT Pediatric Diseases and Late Effects Working Parties Bone Marrow Transplant 2007 39 667 675 17401396
  6. [10]Lonnerholm G Arvidson J Andersson LG Myocardial function after autologous bone marrow transplantation in children: a prospective long-term study Acta Paediatr 1999 88 186 192 10102153
  7. [12]Armenian SH Sun CL Kawashima T Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS) Blood 2011 118 1413 1420 21652685 PMC3152502
  8. [18]van Dalen EC van der Pal HJ Kok WE Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study Eur J Cancer 2006 42 3191 3198 16987655
  9. [19]Pein F Sakiroglu O Dahan M Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy Br J Cancer 2004 91 37 44 15162142 PMC2364747
  10. [20]Green DM Grigoriev YA Nan B Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study group J Clin Oncol 2001 19 1926 1934 11283124
  11. [21]Kremer LC van Dalen EC Offringa M Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review Ann Oncol 2002 13 503 512 12056699
  12. [22]Brouwer CA Postma A Vonk JM Systolic and diastolic dysfunction in long-term adult survivors of childhood cancer Eur J Cancer 2011 47 2453 2462 21696947
  13. [23]van der Pal HJ van Dalen EC Hauptmann M Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study Arch Intern Med 2010 170 1247 1255 20660845
  14. [24]Abosoudah I Greenberg ML Ness KK Echocardiographic surveillance for asymptomatic late-onset anthracycline cardiomyopathy in childhood cancer survivors Pediatr Blood Cancer 2011 57 467 472 21280201
  15. [25]Hudson MM Rai SN Nunez C Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors J Clin Oncol 2007 25 3635 3643 17704413
  16. [27]Lipshultz SE Lipsitz SR Sallan SE Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia J Clin Oncol 2005 23 2629 2636 15837978
  17. [28]Sorensen K Levitt GA Bull C Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study Cancer 2003 97 1991 1998 12673729
  18. [29]Kremer LC van der Pal HJ Offringa M Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review Ann Oncol 2002 13 819 829 12123328
  19. [30]Schellong G Riepenhausen M Bruch C Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies Pediatr Blood Cancer 2010 55 1145 1152 20734400
  20. [31]Aleman BM van den Belt-Dusebout AW De Bruin ML Late cardiotoxicity after treatment for Hodgkin lymphoma Blood 2007 109 1878 1886 17119114
  21. [34]van der Pal HJ van Dalen EC Kremer LC Risk of morbidity and mortality from cardiovascular disease following radiotherapy for childhood cancer: a systematic review Cancer Treat Rev 2005 31 173 185 15896910
  22. [39]Postma A Bink-Boelkens MT Beaufort-Krol GC Late cardiotoxicity after treatment for a malignant bone tumor Med Pediatr Oncol 1996 26 230 237 8600333
  23. [40]Pihkala J Saarinen UM Lundstrom U Effects of bone marrow transplantation on myocardial function in children Bone Marrow Transplant 1994 13 149 155 8205083
  24. [41]Krawczuk-Rybak M Dakowicz L Hryniewicz A Cardiac function in survivors of acute lymphoblastic leukaemia and Hodgkin's lymphoma J Paediatr Child Health 2011 47 455 459 21332587
  25. [42]Mavinkurve-Groothuis AM Groot-Loonen J Bellersen L Abnormal NT-pro-BNP levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines Pediatr Blood Cancer 2009 52 631 636 19127569
  26. [43]Hayakawa H Komada Y Hirayama M Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer Med Pediatr Oncol 2001 37 4 9 11466716
  27. [44]Sherief LM Kamal AG Khalek EA Biomarkers and early detection of late onset anthracycline-induced cardiotoxicity in children Hematology 2012 17 151 156 22664114
  28. [45]Kismet E Varan A Ayabakan C Serum troponin T levels and echocardiographic evaluation in children treated with doxorubicin Pediatr Blood Cancer 2004 42 220 224 14752858
  29. [46]Soker M Kervancioglu M Plasma concentrations of NT-pro-BNP and cardiac troponin-I in relation to doxorubicin-induced cardiomyopathy and cardiac function in childhood malignancy Saudi Med J 2005 26 1197 1202 16127512
  30. [50]Armstrong GT Plana JC Zhang N Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging J Clin Oncol 2012 30 2876 2884 22802310 PMC3671529
  31. [51]Heidenreich PA Gubens MA Fonarow GC Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction J Am Coll Cardiol 2004 43 1019 1026 15028361
  32. [53]Bar J Davidi O Goshen Y Pregnancy outcome in women treated with doxorubicin for childhood cancer Am J Obstet Gynecol 2003 189 853 857 14526329
  33. [54]van Dalen EC van der Pal HJ van den Bos C Clinical heart failure during pregnancy and delivery in a cohort of female childhood cancer survivors treated with anthracyclines Eur J Cancer 2006 42 2549 2553 16919450
  34. [55]Silber JH Cnaan A Clark BJ Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines J Clin Oncol 2004 22 820 828 14990637
  35. [57]Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators N Engl J Med 1991 325 293 302 2057034
  36. [62]Hunt SA Abraham WT Chin MH 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation J Am Coll Cardiol 2009 53 e1 e90 19358937
  37. [64]Dargie HJ Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial Lancet 2001 357 1385 1390 11356434
  38. [65]Exner DV Dries DL Waclawiw MA Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction J Am Coll Cardiol 1999 33 916 923 10091816
  39. [66]Vantrimpont P Rouleau JL Wun CC Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators J Am Coll Cardiol 1997 29 229 236 9014971
  40. [67]Konstam MA Neaton JD Poole-Wilson PA Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II) Am Heart J 2005 150 123 131 16084158
  41. [69]Huang TT Ness KK Exercise interventions in children with cancer: a review Int J Pediatr 2011 2011 461512 22121378 PMC3205744
  42. [71]Pelliccia A Corrado D Bjornstad HH Recommendations for participation in competitive sport and leisure-time physical activity in individuals with cardiomyopathies, myocarditis and pericarditis Eur J Cardiovasc Prev Rehabil 2006 13 876 885 17143118
  43. [72]Maron BJ Chaitman BR Ackerman MJ Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases Circulation 2004 109 2807 2816 15184297

Cited by

Sorted by citations

Related

Authors
Armenian, S. H., Hudson, M. M., Mulder, R. L., Chen, M. H., Constine, L. S., Dwyer, M., Nathan, P. C., Tissing, W. J. E., Shankar, S., Sieswerda, E., Skinner, R., Steinberger, J., van Dalen, E. C., van der Pal, H., Wallace, W. H., Levitt, G., & Kremer, L. C. M.
Affiliations
  • City Of Hope National Medical Center (US)
  • St. Jude Children's Research Hospital (US)
  • Boston Children's Hospital (US)
  • University of Rochester Medicine (US)
  • Peter MacCallum Cancer Centre (AU)
  • University of Toronto (CA)
  • University Medical Center Groningen (NL)
  • Children's National (US)
  • Amsterdam UMC Location University of Amsterdam (NL)
  • Great North Children's Hospital (GB)
  • University of Minnesota (US)
  • Royal Hospital for Sick Children (GB)
  • Great Ormond Street Hospital (GB)
ORCID
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2015-03
Volume
16
Issue
3
Pages
e123-e136
ISSN
1470-2045 (ISSN-L)
DOI
10.1016/s1470-2045(14)70409-7
PMC
PMC4485458
OpenAlex
W2003747306
Cited by
570
References
148
Citations by year
2026: 25 · 2025: 30 · 2024: 46 · 2023: 67 · 2022: 89 · 2021: 61 · 2020: 64 · 2019: 44 · 2018: 45 · 2017: 32 · 2016: 43 · 2015: 20 · 2014: 2 · 2013: 1
FWCI
33.94
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Pure Amsterdam UMC (submittedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
  • Newcastle University ePrints (Newcastle Univesity)
Funders
  • National Cancer Institute (CA21765, K12CA001727, U10CA098543, R01CA113930, P30CA021765)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK072124)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Childhood Cancer Survivors' Quality of Life
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac tumors and thrombi
Keywords
childhood cancer survivors, late effects of cancer treatment, anthracycline cardiotoxicity, congestive heart failure, quality of evidence grading, early detection and intervention
MeSH terms
Adult, Age Factors, Antibiotics, Antineoplastic, Child, Child, Preschool, Cooperative Behavior, Diagnostic Imaging, Echocardiography, Humans, International Cooperation, Magnetic Resonance Imaging, Cardiomyopathies, Neoplasms, Predictive Value of Tests, Radiation Injuries, Radionuclide Angiography, Radiotherapy, Risk Factors, Time Factors, Biomarkers, Treatment Outcome, Survivors, Risk Assessment, Anthracyclines, Evidence-Based Medicine, Consensus, Early Diagnosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review